Novartis Institutes for BioMedical Research, Inc. (“Novartis”) has entered into a license agreement with Housey Pharma to utilize its core-enabling technology platform for new drug discovery. Novartis is one of the world’s top research-based pharmaceutical companies and has an impressive record of key advancements in medicine. Novartis invented the world’s first molecularly targeted cancer treatment, imatinib mesylate for the treatment of certain types of leukemia, which ushered in the next generation of oncology drugs. Novartis continues to innovate in oncology today with numerous innovative medicines at various stages of clinical testing.
Housey Pharma’s platform technology enables the creation and discovery of effective medicines for treating “undruggable” targets that are found in many human diseases, such as drug-resistant cancers, diabetes, neurodegenerative disorders including dementia, and many other disease states.
“Breakthroughs in the discovery and development of new medicines are enabled through the use of this advanced technology platform for new drug discovery,” said Dr. Gerard Housey, co-founder of the company. We look forward to seeing innovative new medicines that benefit people around the world brought forth by our scientific colleagues at Novartis as well as our many other technology licensees.”
